First page of the Report "FDA FY2020 Drug Observations and Trends"

Report – FDA FY2020 Drug Observations and Trends

By

Barbara W. Unger

,

Areas examined in this report:

Data from FY2020 FDA drug GMP inspections
Trends from five years of GMP inspections
Conclusions drawn from an analysis of drug inspection data

If you have trouble with the form, please contact events@redica.com.

Access the white paper

If you have trouble with the form, please contact events@redica.com.